Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference

November 7, 2007

Garo Armen, CEO

Instructions:

1. You must have PowerPoint or PowerPoint-compatible software to view this presentation, preferably PowerPoint 2003 or later.
2. If you are using Internet Explorer, click the button below to view the presentation (will open in a new window). When prompted for a password, please click the “Read-only” button.
3. If you aren’t using Internet Explorer, right-click the button below (control-click for Macs) to download the presentation to your computer. Double-click the downloaded file to view in PowerPoint.

(1.4 MB)

Audio webcast replay

This presentation contains forward-looking statements including statements regarding the company’s lead product candidates Oncophage^® (vitespen; formerly HSPPC-96), QS-21™, AG-707 and Aroplatin™ (including, but not limited to, the timing of product development, launch and product revenues), the successful development of the Company’s products by collaborative partners, the company’s clinical trials (including, but not limited to, trial initiation, enrollment, completion, analysis and interpretation of results), the confirmation of Oncophage subgroup analyses, the regulatory approval process (including, but not limited to, dates and locations of filings), research programs and other future events and operations. These forward-looking statements involve uncertainties and risks that are described under Risk Factors of Antigenics’ Form 10-Q as filed with the Securities and Exchange Commission on August 9, 2007. Actual results could differ materially from these forward-looking statements.